Sensitive and selective quantification of total and free itraconazole and hydroxyitraconazole in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry.

[1]  J. Ware,et al.  Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  I. Yano,et al.  Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach. , 2015, Drug metabolism and pharmacokinetics.

[3]  B. Tan,et al.  Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis , 2015, Antimicrobial Agents and Chemotherapy.

[4]  R. Ostini,et al.  Exploratory Study of Total and Free Prednisolone Plasma Exposure and Cushingoid Appearance, Quality of Life and Biochemical Toxicity in Adult Male Kidney Transplant Recipients , 2015, Clinical Drug Investigation.

[5]  Liang-Shang Gan,et al.  Plasma protein binding: from discovery to development. , 2013, Journal of pharmaceutical sciences.

[6]  M. Cuenca‐Estrella,et al.  A simple, sensitive HPLC-PDA method for the quantification of itraconazole and hydroxy itraconazole in human serum: a reference laboratory experience. , 2013, Diagnostic microbiology and infectious disease.

[7]  S. Zhai,et al.  Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma , 2012, Clinical chemistry and laboratory medicine.

[8]  Jinny Park,et al.  The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observa , 2013, Annals of Hematology.

[9]  H. Itoh,et al.  Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy. , 2012, Biological & pharmaceutical bulletin.

[10]  R. Aarnoutse,et al.  Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  D. Denning,et al.  Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Andes,et al.  Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.

[13]  R. Kimura,et al.  Hydroxyitraconazole, Formed During Intestinal First-Pass Metabolism of Itraconazole, Controls the Time Course of Hepatic CYP3A Inhibition and the Bioavailability of Itraconazole in Rats , 2008, Drug Metabolism and Disposition.

[14]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Drew,et al.  Antifungal serum concentration monitoring: an update. , 2007, The Journal of antimicrobial chemotherapy.

[16]  Stefanie Hennig,et al.  A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. , 2007, British journal of clinical pharmacology.

[17]  Y. L. Loukas,et al.  Development of a high-throughput method for the determination of itraconazole and its hydroxy metabolite in human plasma, employing automated liquid–liquid extraction based on 96-well format plates and LC/MS/MS , 2006, Analytical and bioanalytical chemistry.

[18]  S. Bell,et al.  Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients , 2006, Clinical pharmacokinetics.

[19]  W. L. Nelson,et al.  ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION , 2004, Drug Metabolism and Disposition.

[20]  B. Djulbegovic,et al.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Derendorf,et al.  Antimicrobial tissue concentrations. , 2003, Infectious disease clinics of North America.

[22]  Qinying Zhao,et al.  Pharmacokinetics of Intravenous Itraconazole followed by Itraconazole Oral Solution in Patients with Human Immunodeficiency Virus Infection , 2001, Journal of clinical pharmacology.

[23]  F. Odds,et al.  Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. , 2000, The Journal of antimicrobial chemotherapy.

[24]  J. Vazquez,et al.  Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus. , 1999, The Journal of antimicrobial chemotherapy.

[25]  G. Cheymol,et al.  Optimisation of Itraconazole Therapy Using Target Drug Concentrations , 1998, Clinical pharmacokinetics.

[26]  J. Decruyenaere,et al.  Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units , 1997, Antimicrobial agents and chemotherapy.

[27]  B. Gazzard,et al.  Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. , 1997, Journal of clinical pathology.

[28]  E. Suárez,et al.  Protein binding of itraconazole and fluconazole in patients with cancer. , 1995, International journal of clinical pharmacology and therapeutics.

[29]  E. Suárez,et al.  Protein binding of itraconazole and fluconazole in patients with chronic renal failure. , 1994, International journal of clinical pharmacology and therapeutics.

[30]  Y. Ueno,et al.  Comparison of in vitro antifungal activity of itraconazole and hydroxy‐itraconazole by colorimetric MTT assay , 1994, Mycoses.

[31]  G. Rolinson,et al.  Effect of protein binding on antibiotic activity in vivo. , 1983, The Journal of antimicrobial chemotherapy.

[32]  A. Goldstein.  The interactions of drugs and plasma proteins. , 1949, The Journal of pharmacology and experimental therapeutics.